Ventures
Invest in breakthrough healthtech solutions that transform patients' lives.

Receive the latest investment opportunities that match your interests, directly in your inbox. Stay informed and never miss out.
a highlight from our portfolio

Angiogenesis Analytics

PEP Health
Pasithea improves treating obstructive sleep apnea (OSA), a condition affecting millions worldwide. Traditional treatments like continuous positive airway pressure (CPAP) face high refusal and dropout rates. Pasithea offers a non-invasive solution based on triggered kinesthetic stimulation. By detecting early signs of apnea or hypopnea and inducing a controlled response, Pasithea activates muscle control centers to prevent oxygen desaturation and associated cardiovascular risks, aiming to improve patient compliance and outcomes.

FlowView Diagnostics addresses the challenge of analyzing complex cell data from blood samples using multiparameter flow cytometry, vital for conditions like leukemia monitoring. They tackle this with an algorithm that quickly processes raw data, detecting Minimal Residual Disease (MRD) more accurately and rapidly than manual methods. In a case study, the algorithm analyzed 8 million cells in 2 minutes, presenting simplified results for quicker interpretation, reducing the risk of false negatives, and enhancing efficiency in leukemia monitoring.

The rising number of surgeries in healthcare systems like the National Health Service is challenging due to increasing demand and backlogs. However, new solutions like the Asclepius Platform aim to streamline assessments before and after surgery using digital tools and AI. By analyzing patient data, it helps doctors make better decisions, reduce complications, and improve patient outcomes. Designed with input from patients, it's a cost-effective way to make surgery safer and more efficient.

Lamina offers a solution for the regeneration of cartilage, addressing a prevalent issue affecting millions worldwide. Traditional treatments focus on symptom management or procedures like joint replacement, with limited success. Lamina's ARTiREG, enhances cell therapy with a special framework to hold Mesenchymal stem cells which repair for the body and help fix damaged cartilage. This patented approach promotes fast recovery, potentially transforming outcomes for individuals with cartilage damage.

Hemeo addresses the challenge of treating ICU patients with coagulation issues by developing a decision support system. This system uses patient data and real-time monitoring to accurately assess bleeding and thrombosis risks. By modeling the coagulation system with a smart algorithm, it provides personalized recommendations to clinicians, helping them make more informed therapy decisions. With ICU patients at high risk for venous thromboembolism and bleeding incidents, this solution aims to improve patient outcomes and reduce uncertainty in treatment.

The traditional practice of immediately cutting the umbilical cord after birth can pose risks to newborns, causing a dangerous drop in blood flow and oxygen levels. Concord Neonatal offers a solution by allowing babies to receive lifesaving care with the umbilical cord intact until they start breathing on their own. This innovation, aims to prevent birth complications and long-term disabilities, while keeping the baby close to the mother and maximizing the benefits of placental blood until the baby can breathe independently.

Foveo Fertility addresses the challenge of improving in vitro fertilization (IVF) success rates by providing a stable physiological environment for egg cells. Unlike current methods that expose egg cells to air, leading to cooling and evaporation, Foveo Fertility ensures consistent conditions for optimal egg cell quality. This innovation also streamlines workflow in the IVF lab, reducing human error and saving time for embryologists. With no other product on the market offering constant physiological conditions for egg cells, Foveo Fertility aims to improve the lives of both lab workers and patients by maximizing the potential for successful pregnancies.

NC Biomatrix offers a solution for treating chronic back pain caused by intervertebral disc degeneration. Current treatments only address symptoms, have limited effectiveness and often come with complications. NC Biomatrix introduces a new approach using a bio-inductive protein extract obtained from porcine notochordal biomatrix. This injectable treatment addresses the underlying pathology and aims to restore the degenerated disc as a way to definitively treat chronic back pain.

Our impact
Explore our 2024 Impact report

Invest in a portfolio of companies
